Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076).
Elizabeth Ellen TolleySue LiSahar Z ZangenehMillicent AtujunaPetina MusaraJessica JustmanSubash PathakLinda-Gail BekkerShobha SwaminathanJill StantonJennifer FarriorNirupama SistaPublished in: Journal of the International AIDS Society (2020)
This study found that long-acting injectable PrEP is acceptable among African and US women experiencing product use. Acceptability of product attributes better predicted future interest in injectable use than experience of pain. This is reassuring as a single-dose regimen of a different product has advanced to phase 3 trials. Finally, the study suggests that future demand for an injectable PrEP by women may be greater in African than US settings, where the risk of HIV is highest.
Keyphrases
- polycystic ovary syndrome
- clinical trial
- hyaluronic acid
- men who have sex with men
- chronic pain
- current status
- hiv positive
- tissue engineering
- hiv infected
- breast cancer risk
- randomized controlled trial
- adipose tissue
- pregnant women
- pain management
- hiv aids
- spinal cord
- study protocol
- open label
- insulin resistance
- spinal cord injury
- skeletal muscle
- south africa